Development of a novel fully functional coagulation factor VIII with reduced immunogenicity utilizing an in silico prediction and deimmunization approach-Reference-Cited by-同舟云学术

Development of a novel fully functional coagulation factor VIII with reduced immunogenicity utilizing an in silico prediction and deimmunization approach

Published:2021-06-30 Issue:9 Volume:19 Page:2161-2170
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J. Thromb. Haemost.

Author:

Winterling Karina¹,Martin William D.²,De Groot Anne S.²³,Daufenbach Jens¹,Kistner Steffen¹,Schüttrumpf Jörg¹

Affiliation:

1. Biotest AG Dreieich Germany

2. EpiVax, Inc. Providence Rhode Island USA

3. Center for Vaccines and Immunology University of Georgia Athens Georgia USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.15413

Reference45 articles.

1. Molecular basis of haemophilia A

2. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis

3. Different impact of factor VIII products on inhibitor development?;Berg HM;Thrombosis J,2016

4. Factor VIII inhibitors in mild and moderate-severity haemophilia A

5. Immunogenicity of protein therapeutics

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Engineered Flt3L Drives Tolerogenic State to Attenuate Anti-drug Antibody Responses;2024-03-27

2. T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics;mAbs;2024-03-21

3. Machine learning for functional protein design;Nature Biotechnology;2024-02

4. Accelerating antibody discovery and design with artificial intelligence: Recent advances and prospects;Seminars in Cancer Biology;2023-10

5. Immunoinformatic Risk Assessment of Host Cell Proteins During Process Development for Biologic Therapeutics;The AAPS Journal;2023-09-11